Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2002 Jul;39(7):457–462. doi: 10.1136/jmg.39.7.457

The effect of a single BRCA2 mutation on cancer in Iceland

H Tulinius 1, G Olafsdottir 1, H Sigvaldason 1, A Arason 1, R Barkardottir 1, V Egilsson 1, H Ogmundsdottir 1, L Tryggvadottir 1, S Gudlaugsdottir 1, J Eyfjord 1
PMCID: PMC1735175  PMID: 12114473

Abstract

Objective: To estimate the risk of malignant diseases in families of probands with the same mutation in the BRCA2 gene.

Design: A cohort study using record linkage of a breast cancer family resource and the Icelandic Cancer Registry.

Setting: Iceland.

Subjects: Families of 995 breast cancer patients, from which 887 were tested for a single founder 999del5 mutation; 90 had the mutation and 797 did not.

Results: Relatives of probands with the mutation had significantly increased relative risk (RR) of breast cancer. For first degree relatives, the RR was 7.55 (95% CI 6.04 to 9.03) but was 1.72 (95% CI 1.49 to 1.96) in first degree relatives of probands without the mutation. For prostate and ovarian cancer, the first and second degree relatives of probands with the mutation had a significantly increased RR, but in families of probands without the mutation no significant familial risk was found.

Conclusions: The 999del5 mutation in the BRCA2 gene explains a substantial proportion of familial risk of breast cancer in Iceland, but significant familial risk remains in relatives of probands without the mutation. For prostate and ovarian cancer, the mutation accounts for most of the familiality observed in families of breast cancer patients.

Full Text

The Full Text of this article is available as a PDF (159.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoniou A. C., Pharoah P. D., McMullan G., Day N. E., Ponder B. A., Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001 Jul;21(1):1–18. doi: 10.1002/gepi.1014. [DOI] [PubMed] [Google Scholar]
  2. Arason A., Jonasdottir A., Barkardottir R. B., Bergthorsson J. T., Teare M. D., Easton D. F., Egilsson V. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet. 1998 Jun;35(6):446–449. doi: 10.1136/jmg.35.6.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baffoe-Bonnie A. B., Beaty T. H., Bailey-Wilson J. E., Kiemeney L. A., Sigvaldason H., Olafsdóttir G., Tryggvadóttir L., Tulinius H. Genetic epidemiology of breast cancer: segregation analysis of 389 Icelandic pedigrees. Genet Epidemiol. 2000 Jan;18(1):81–94. doi: 10.1002/(SICI)1098-2272(200001)18:1<81::AID-GEPI6>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  4. Bergthorsson J. T., Jonasdottir A., Johannesdottir G., Arason A., Egilsson V., Gayther S., Borg A., Hakanson S., Ingvarsson S., Barkardottir R. B. Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat. 1998;Suppl 1:S195–S197. doi: 10.1002/humu.1380110163. [DOI] [PubMed] [Google Scholar]
  5. Dunning A. M., Healey C. S., Pharoah P. D., Teare M. D., Ponder B. A., Easton D. F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):843–854. [PubMed] [Google Scholar]
  6. Goldgar D. E., Easton D. F., Cannon-Albright L. A., Skolnick M. H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994 Nov 2;86(21):1600–1608. doi: 10.1093/jnci/86.21.1600. [DOI] [PubMed] [Google Scholar]
  7. Gudmundsson J., Johannesdottir G., Arason A., Bergthorsson J. T., Ingvarsson S., Egilsson V., Barkardottir R. B. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet. 1996 Apr;58(4):749–756. [PMC free article] [PubMed] [Google Scholar]
  8. Healey C. S., Dunning A. M., Teare M. D., Chase D., Parker L., Burn J., Chang-Claude J., Mannermaa A., Kataja V., Huntsman D. G. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000 Nov;26(3):362–364. doi: 10.1038/81691. [DOI] [PubMed] [Google Scholar]
  9. Johannesdottir G., Gudmundsson J., Bergthorsson J. T., Arason A., Agnarsson B. A., Eiriksdottir G., Johannsson O. T., Borg A., Ingvarsson S., Easton D. F. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996 Aug 15;56(16):3663–3665. [PubMed] [Google Scholar]
  10. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  11. Sigurdsson S., Thorlacius S., Tomasson J., Tryggvadottir L., Benediktsdottir K., Eyfjörd J. E., Jonsson E. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl) 1997 Oct;75(10):758–761. doi: 10.1007/s001090050162. [DOI] [PubMed] [Google Scholar]
  12. Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337. doi: 10.1038/ng0396-333. [DOI] [PubMed] [Google Scholar]
  13. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. doi: 10.1038/ng0596-117. [DOI] [PubMed] [Google Scholar]
  14. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjörd J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997 May;60(5):1079–1084. [PMC free article] [PubMed] [Google Scholar]
  15. Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjörd J. E. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998 Oct 24;352(9137):1337–1339. doi: 10.1016/s0140-6736(98)03300-5. [DOI] [PubMed] [Google Scholar]
  16. Thorlacius S., Tryggvadottir L., Olafsdottir G. H., Jonasson J. G., Ogmundsdottir H. M., Tulinius H., Eyfjord J. E. Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995 Aug 26;346(8974):544–545. doi: 10.1016/s0140-6736(95)91383-1. [DOI] [PubMed] [Google Scholar]
  17. Tulinius H., Day N. E., Bjarnason O., Geirsson G., Johannesson G., Liceaga de Gonzalez M. A., Sigvaldason H., Bjarnadottir G., Grimsdottir K. Familial breast cancer in Iceland. Int J Cancer. 1982 Apr 15;29(4):365–371. doi: 10.1002/ijc.2910290402. [DOI] [PubMed] [Google Scholar]
  18. Tulinius H., Egilsson V., Olafsdóttir G. H., Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992 Oct 10;305(6858):855–857. doi: 10.1136/bmj.305.6858.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tulinius H., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Bjarnadottir K. Neoplastic diseases in families of breast cancer patients. J Med Genet. 1994 Aug;31(8):618–621. doi: 10.1136/jmg.31.8.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tulinius H., Sigvaldason H., Olafsdóttir G., Tryggvadóttir L., Bjarnadóttir K. Breast cancer incidence and familiality in Iceland during 75 years from 1921 to 1995. J Med Genet. 1999 Feb;36(2):103–107. [PMC free article] [PubMed] [Google Scholar]
  21. Tulinius H., Sigvaldason H., Olafsdóttir G., Tryggvadóttir L. Epidemiology of breast cancer in families in Iceland. J Med Genet. 1992 Mar;29(3):158–164. doi: 10.1136/jmg.29.3.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weber B. L., Nathanson K. L. Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 2000 Jun;36(10):1193–1199. doi: 10.1016/s0959-8049(00)00082-4. [DOI] [PubMed] [Google Scholar]
  23. Weston A., Godbold J. H. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997 Jun;105 (Suppl 4):919–926. doi: 10.1289/ehp.97105s4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES